These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24682249)

  • 1. Effect of bosentan therapy on ventricular and atrial function in adults with Eisenmenger syndrome. A prospective, multicenter study using conventional and Speckle tracking echocardiography.
    Abd El Rahman MY; Rentzsch A; Scherber P; Mebus S; Miera O; Balling G; Böttler P; Dubowy KO; Farahwaschy B; Hager A; Kreuder J; Peters B; Berger F; Schulze-Neick I; Abdul-Khaliq H
    Clin Res Cardiol; 2014 Sep; 103(9):701-10. PubMed ID: 24682249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.
    D'Alto M; Romeo E; Argiento P; Sarubbi B; Santoro G; Grimaldi N; Correra A; Scognamiglio G; Russo MG; Calabrò R
    Int J Cardiol; 2012 Mar; 155(3):378-82. PubMed ID: 21081251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.
    Galiè N; Beghetti M; Gatzoulis MA; Granton J; Berger RM; Lauer A; Chiossi E; Landzberg M;
    Circulation; 2006 Jul; 114(1):48-54. PubMed ID: 16801459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
    Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
    Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome.
    Kaya MG; Lam YY; Erer B; Ayhan S; Vatankulu MA; Nurkalem Z; Meric M; Eren M; Eryol NK
    J Card Fail; 2012 May; 18(5):379-84. PubMed ID: 22555267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
    Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
    Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of bosentan in adults with Eisenmenger physiology.
    Gatzoulis MA; Rogers P; Li W; Harries C; Cramer D; Ward S; Mikhail GW; Gibbs JS
    Int J Cardiol; 2005 Jan; 98(1):147-51. PubMed ID: 15676179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study.
    Gatzoulis MA; Beghetti M; Galiè N; Granton J; Berger RM; Lauer A; Chiossi E; Landzberg M;
    Int J Cardiol; 2008 Jun; 127(1):27-32. PubMed ID: 17658633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial.
    Schuuring MJ; Vis JC; van Dijk AP; van Melle JP; Vliegen HW; Pieper PG; Sieswerda GT; de Bruin-Bon RH; Mulder BJ; Bouma BJ
    Eur J Heart Fail; 2013 Jun; 15(6):690-8. PubMed ID: 23361871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects.
    Mehta PK; Simpson L; Lee EK; Lyle TA; McConnell ME; Book WM
    Tex Heart Inst J; 2008; 35(3):256-61. PubMed ID: 18941642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pulmonary vasodilator therapy on ventilatory efficiency during exercise in adults with Eisenmenger syndrome.
    Yang-Ting S; Aboulhosn J; Sun XG; Child JS; Sietsema KE
    Congenit Heart Dis; 2011; 6(2):139-46. PubMed ID: 21418531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down patients with Eisenmenger syndrome: is bosentan treatment an option?
    Duffels MG; Vis JC; van Loon RL; Berger RM; Hoendermis ES; van Dijk AP; Bouma BJ; Mulder BJ
    Int J Cardiol; 2009 May; 134(3):378-83. PubMed ID: 18579234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy.
    D'Alto M; Romeo E; Argiento P; Santoro G; Sarubbi B; Gaio G; Mélot C; Russo MG; Naeije R; Calabrò R
    Heart; 2010 Sep; 96(18):1475-9. PubMed ID: 20668108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Speckle-tracking imaging in patients with Eisenmenger syndrome.
    Moceri P; Iriart X; Bouvier P; Baudouy D; Gibelin P; Saady R; Laïk J; Cerboni P; Thambo JB; Ferrari E
    Arch Cardiovasc Dis; 2016 Feb; 109(2):104-12. PubMed ID: 26868160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of bosentan in adults with simple and complex Eisenmenger's syndrome.
    Williams R; Houser L; Miner P; Aboulhosn J
    Congenit Heart Dis; 2012; 7(1):12-5. PubMed ID: 22188797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of an endothelin receptor antagonist in Eisenmenger syndrome: a single-center experience of 11 patients].
    Poindron D; Godart F; Duhamel A; Richard A; Francart C; Brevière GM; Rey C
    Arch Mal Coeur Vaiss; 2006 May; 99(5):457-62. PubMed ID: 16802735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial.
    Iversen K; Jensen AS; Jensen TV; Vejlstrup NG; Søndergaard L
    Eur Heart J; 2010 May; 31(9):1124-31. PubMed ID: 20202971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: a subgroup analysis.
    Berger RM; Beghetti M; Galiè N; Gatzoulis MA; Granton J; Lauer A; Chiossi E; Landzberg M
    Int J Cardiol; 2010 Oct; 144(3):373-8. PubMed ID: 19464064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension.
    Dimitroulas T; Giannakoulas G; Karvounis H; Koliakos G; Sfetsios T; Dimitroula H; Settas L
    Clin Rheumatol; 2008 May; 27(5):655-8. PubMed ID: 18204995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of right ventricular longitudinal strain by 2D speckle tracking imaging compared with RV function and hemodynamics in pulmonary hypertension.
    Li Y; Wang Y; Meng X; Zhu W; Lu X
    Int J Cardiovasc Imaging; 2017 Nov; 33(11):1737-1748. PubMed ID: 28553693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.